Table 1.
List of clinical trials investigating neurological applications of MRgFUS by disorder
| Indication | Stage | Description |
|---|---|---|
| ET | Phase II |
NCT02289560 – multi-centered, single arm study to look at efficacy for ET NCT01827904 - prospective, randomized, double blind, crossover, multi-centered, two arm study to test efficacy and further demonstrate safety |
| PD | Phase I | NCT02347254, NCT01772693, NCT02263885, NCT02246374, NCT02252380 - phase I trial to study unilateral Vim nucleus/subthalamic nucleus/globus pallidus sonication for PD |
| Brain tumor – ablation | Phase I |
NCT00147056, NCT02343991, NCT01473485 – phase I trial for tumor ablation, ongoing NCT01698437 – phase I trial for tumor ablation, completed, University Children’s Hospital in Zurich |
| Brain tumor – BBB disruption | Phase I | NCT02343991 – phase I trial to study BBB opening for delivery of doxorubicin |
| Depression/anxiety | Phase I |
NCT02348411 – phase I trial to study safety and initial effectiveness of MRgFUS bilateral anterior capsulotomy in medication-refractory MDD NCT02685488 – phase I trial of right frontotemporal area sonication for mild to moderate depression |
| OCD | Phase I |
NCT01986296 - phase I trial of anterior cingulate cortex, anterior limb of internal capsule, ventral striatum or subgenual cingulate cortex sonication NCT03156335 - phase I trial to evaluate the safety and efficacy of MRgFUS for patients with treatment-refractory OCD |
| Pain syndromes | Phase I |
NCT01699477 - phase I trial of thalamic sonication for neuropathic pain, pediatric, University Children’s Hospital in Zurich Central lateral thalamic nucleus sonication (Neurosurgery Focus 2012) NCT03111277 - phase I trial for MRgFUS thalamotomy of central lateral thalamic nucleus |
| Epilepsy – ablation | Phase I | NCT02804230 – phase I trial, ablation of subcortical focal epileptic targets |
| Epilepsy - neuromodulation | Phase I | NCT02151175 – phase I trial, stimulation or suppression of neuronal activity in temporal lobe |
| AD | Phase I | NCT02986932 – phase I trial of ultrasound mediated BBB opening for AD |
| Thrombolysis/ICH | Preclinical | Swine and human cadaveric models demonstrated feasibility of ICH liquefaction. Rabbit carotid occlusion model demonstrated feasibility of this model for vascular recanalization |
| CSF diversion | Preclinical | Proof-of principle study of MRgFUS third ventriculostomy |
| Neuromodulation | Phase I | Vagus nerve modulation can stimulate or dampen neuronal activity |
ET essential tremor, PD Parkinson’s disease, BBB blood-brain barrier, MDD major depressive disorder, OCD obsessive compulsive disorder, AD Alzheimer’s disease, CSF cerebrospinal fluid, FUS focused ultrasound, ICH intracerebral hemorrhage, NCT national clinical trial (number)